EPHA2 and glioblastoma: Recently, a novel TanCAR targeting interleukin-13 receptor subunit alpha-2 (IL-13Rα2) and ephrin type-A receptor 2 (EphA2) was shown to be effective in both in vitro and in vivo glioblastoma (GBM) models.